Adicet Bio Inc
ACET
Get informed when a big investor buys or sells
+ FollowMarket Cap$74.6M
Close$
$3.51
57.5% downside
Current Fair Value
57.5% downsideOvervalued by 57.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $74.60 Million |
|---|---|
| Enterprise Value | $54.32 Million |
| Dividend Yield | $0.15 (-) |
| Earnings per Share | $-16.95 |
| Beta | 1.59 |
| Outstanding Shares | 10,745,553 |
Return
| Return on Equity | -82.38% |
|---|---|
| Return on Assets | -66.80% |
| Return on Invested Capital | -81.01% |
Valuation & Multiples
| P/E Ratio | -0.7 |
|---|---|
| PEG | 2.21 |
| Price to Sales | - |
| Price to Book Ratio | 0.75 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.52 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.69
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 52,900▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 59.10%▼ 38.43% |
|---|---|
| Total Invested | $43.25M▼ 23.56% |
| Investors Holding | 490% |
ESG Score
No data
About Adicet Bio, Inc.
152 employees
CEO: Mr. Chen Schor BA, CPA, M.B.A. Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell recepto...